Akademik Veri Yönetim Sistemi
European Journal of Obstetrics and Gynecology and Reproductive Biology, cilt.130, sa.2, ss.206-211, 2007 (SCI-Expanded)
Objective: The objective was to determine the effects of transdermal and oral hormone replacement therapies on plasma total homocysteine levels in postmenopausal women. Material and methods: One hundred and ten postmenopausal patients were enrolled in the study. Participants were randomized into three groups: in Group A (n = 31) oral continuous combined therapy and in Group B (n = 30) transdermal sequential hormone replacement therapy were given for 6 months. A placebo was administered orally to the control group (Group C, n = 30). Serum homocysteine levels were studied prior to and after 6 months of treatment in all groups. Results: There were no statistical significant differences in mean serum homocysteine levels among the groups prior to the study. The mean homocysteine levels after 6 months in Groups A-C were also similar. Conclusions: Serum homocysteine levels alter with neither oral continuous nor sequential transdermal hormone replacement therapy. © 2006 Elsevier Ireland Ltd. All rights reserved. Patients:110 female postmenopausal outpatients [age range 44-65 years (mean age 52.5 years)], of whom 92 were included in the study. Oral continuous combined therapy (estradiol hemi-hydrate plus norethisterone acetate) group/Group A: n=31, age range 44-54 years (mean age 50 years). Sequential transdermal Estraderm TTS group/Group B: n=30, age range 48-55 years (mean age 51 years). Placebo group/Group C: n=31, age range 47-52 years (mean age 50 years).TypeofStudy:A study comparing the effects of sequential transdermal Estracombi TTS versus continuous oral estradiol hemi-hydrate plus norethisterone acetate hormone replacement therapies (HRT) on plasma total homocysteine (Hcy) levels in postmenopausal women. A randomized, placebo-controlled study.DosageDuration:0.05 mg given weekly on days 1-14 as 2 transdermal patches. Duration: 6 months.ComparativeDrug:Estradiol hemi-hydrate 1 mg daily plus norethisterone acetate 0.5 mg(Activelle) orally was given on days 1-28. Duration: 6 months.Results:No significant differences were noted between systolic and diastolic blood pressure in any of the groups before and after HRT. Likewise, no significant differences were noted between lipid profile in any of the groups before and after HRT. Mean estradiol blood levels before HRT were similar in the 3 groups (18.5 pg/ml in Group A, 17.6 pg/ml in Group B, and 18.2 pg/ml in the placebo group). After HRT, mean estradiol levels increased with no significant difference noted in Groups A and B (both 89.2 pg/ml). In Group C, the mean estradiol level (15.9 pg/ ml) did not change. Likewise, mean FSH levels decreased after the treatment in Group A (53.5 to 14 IU/l) and Group B (55.2 to 13.8 IU/l). In the placebo group mean FSH levels remained constant (52.8 versus 55.8 IU/l). Mean Hcy levels before HRT were similar in the 3 groups (10.81, 11.71, and 11.31 mcmol/l for Groups A, B and C, respectively). However, mean Hcy levels after HRT in the 3 groups remained the same (11.23, 11.47, and 11.11 mcmol/l, respectively) with no significant difference noted between groups.AdverseEffects:No adverse events were mentioned.AuthorsConclusions:In conclusion, it cannot be ruled out that HRT might have an effect beyond 6 months that cannot be detected by the current study. Yet it is still unclear whether or not HRT reduces plasma total Hcy levels? However, in the current study the plasma total Hcy levels were not reduced or altered after 6 months' continuous use of combined HRT administered orally or sequential use of HRT administered transdermally.FreeText:Tests: blood levels of Hcy, estradiol, follicle stimulating hormone levels (FSH), lipids (cholesterol, triglyceride, high density lipoprotein, and low density lipoprotein); and blood pressure. For the transdermal treatment, Estraderm TTS was given weekly on days 1-14 followed by estradiol plus norethisterone acetate given weekly on days 15-28.